What Lilly tested and what moved the scale
Eli Lilly is stacking an experimental amylin-mimicking compound called eloralintide on top of its hit diabetes drug Mounjaro. In the group receiving both medicines at the strongest dose, patients shed an average of 54 pounds, amounting to as much as 23% of body weight lost. For people with diabetes, who often see slower progress even on today's medicines, that is a striking result.
Blood sugar gains and expert reactions
Beyond the weight change, the high-dose combination cut A1C by 2.9% from a starting average of 8.1%, and as many as three quarters of participants in that arm achieved normal blood sugar. "This could open up even a next frontier in weight loss," said Ken Custer, who leads Lilly's cardiometabolic unit. He noted that, with the usual caveats about cross-trial comparisons, the 48 week results topped the weight reduction seen with Lilly's next-generation shot retatrutide over 80 weeks in a larger study.
"It is a wow," said Julio Rosenstock, a study investigator who holds a professorship in medicine at the University of Texas Southwestern Medical Center. Rosenstock, who once nicknamed Mounjaro "King Kong," said if retatrutide is "Godzilla," then the eloralintide combo would be "the Incredible Hulk." Calling the blood sugar reductions "hugely clinically impactful," Liana Billings, a study leader who leads clinical and genetics research on diabetes and cardiometabolic conditions for Endeavor Health, weighed in.
When headlines highlight breakthroughs, steady investing still matters, so download our free Always Be Buying E-Book to learn more
Side effects and what gets tweaked next
Potent effects came with tradeoffs at the top dose: 27% of participants on the high-dose combo stopped treatment due to side effects. More than 80% of that group reported at least one adverse event, and about half experienced nausea. Custer said the company plans to refine how patients are stepped up to higher doses in upcoming studies to help more people stay on therapy.
The Novo backdrop and what to watch now
Lilly is leaning into amylin-based approaches to defend its lead in the crowded diabetes and obesity market. Success here would put it head to head again with Novo Nordisk A/S, which combined its amylin therapy cagrilintide with Wegovy to create CagriSema. That candidate could get a US decision by year end, though in trials it has repeatedly fallen short of investor hopes for weight loss.
Lilly intends to begin late-stage testing of the eloralintide plus Mounjaro combo by the end of the year. For everyday investors, the thread to follow is simple: strong efficacy, tolerability that needs tuning, and a rivalry heating up as Lilly's stock popped up to 2.6% before giving back some gains.
Even amid medical news, disciplined contributions win over time; get the free Always Be Buying E-Book for a simple plan
